REVANCE THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.085 USD | -2.37% |
|
-6.78% | -64.79% |
Presenter SpeechBalaji Prasad (Analysts)[Audio Gap] the next session of the Barclays Healthcar...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
Sector
Pharmaceuticals
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
3.16
USD
Average target price
13.5
USD
Spread / Average Target
+327.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -64.79% | 330M | |
| -2.32% | 92.59B | |
| +3.68% | 41.43B | |
| -11.44% | 33.49B | |
| -19.22% | 14.62B | |
| -8.95% | 12.77B | |
| -11.34% | 11.58B | |
| -43.53% | 11.35B | |
| +3.75% | 8.97B | |
| -6.32% | 8.3B |
- Stock Market
- Equities
- RVNC Stock
- News Revance Therapeutics, Inc.
- Transcript : Revance Therapeutics, Inc. Presents at Barclays Global Healthcare Conference, Mar-14-2023 09
